
Product Data Sheet

Product Name: Gatipotuzumab

Cat. No.: GC69153

Chemical Properties

Cas. No. 1264737-26-9

Formula M.Wt

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Protocol****Cell experiment [1]:**

Cell lines Ovarian cancer cells (COV318, OV-90, OVCAR-3, SKOV-3)

Preparation Method The ovarian cancer cells were inoculated into 96-well plates at a density of 3000 cells per well and cultured until they reached the logarithmic phase of growth. The cells were then treated with different concentrations of Gatipotuzumab and/or 4-Hydroxy-Tamoxifen (4-OHT) for 48 and 72 hours.

Reaction Conditions 0, 30, 60µg/mL Gatipotuzumab; 0, 5µM 4-OHT; 48 and 72 hours of treatment

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Applications

Gatipotuzumab treatment significantly reduced cell viability, as evidenced by decreased cell proliferation. Co-treatment of ovarian cancer cells with Gatipotuzumab (60µg/mL) and 4-OHT (5µM) further decreased cell viability at 48 and 72 hours, with a more pronounced effect than treatment with Gatipotuzumab or 4-OHT alone.

[1] Heublein S, Page S, Mayr D, et al. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. *Int J Mol Sci.* 2019 Jan 12;20(2):295.

Background

Gatipotuzumab is a humanized monoclonal antibody that specifically targets the tumor-associated mucin-1 (TA-MUC1) epitope and has the potential to inhibit cancer progression^[1]. DLL3 demonstrates high expression levels in small cell lung cancer (SCLC) and other neuroendocrine tumors, while showing minimal expression in normal tissues. This selective targeting mechanism enables Gatipotuzumab to deliver cytotoxic agents specifically to cancer cells expressing DLL3, thereby minimizing impact on healthy cells^[2-3]. Further exploration is underway to investigate its potential utility in treating other DLL3-expressing neuroendocrine tumors^[4].

Gatipotuzumab (0, 30, 60µg/mL) treatment of ovarian cancer cells (COV318, OV-90, OVCAR-3, SKOV-3) significantly reduced cell viability, as evidenced by decreased cell proliferation. Moreover, co-treatment of ovarian cancer cells with Gatipotuzumab (60µg/mL) and 4-hydroxy-tamoxifen (4-OHT, 5µM) further decreased cell viability at 48 and 72 hours, with a more pronounced effect than treatment with Gatipotuzumab or 4-OHT alone^[5].

References:

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

- [1] Ochsenreither S, Fiedler WM, Conte GD, et al. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors. *ESMO Open*. 2022 Apr;7(2):100447.
- [2] Owen DH, Giffin MJ, Bailis JM, et al. DLL3: an emerging target in small cell lung cancer. *J Hematol Oncol*. 2019 Jun 18;12(1):61.
- [3] Heublein S, Page S, Mayr D, et al. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. *Int J Mol Sci*. 2019 Jan 12;20(2):295.
- [4] Heublein S, Friese K, Kost B, et al. TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer. *J Cancer Res Clin Oncol*. 2018 Oct;144(10):1899-1907.
- [5] Heublein S, Page S, Mayr D, et al. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. *Int J Mol Sci*. 2019 Jan 12;20(2):295.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA